Review

Systemic Actions of Breast Cancer Facilitate Functional Limitations

Ruizhong Wang 1 and Harikrishna Nakshatri 1,2,3,*

1 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA; rewang@iupui.edu
2 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3 VA Roudebush Medical Center, Indianapolis, IN 46202, USA
* Correspondence: hnakshat@iupui.edu; Tel.: +1-317-278-2238

Received: 4 December 2019; Accepted: 9 January 2020; Published: 13 January 2020

Abstract: Breast cancer is a disease of a specific organ, but its effects are felt throughout the body. The systemic effects of breast cancer can lead to functional limitations in patients who suffer from muscle weakness, fatigue, pain, fibromyalgia, or many other dysfunctions, which hasten cancer-associated death. Mechanistic studies have identified quite a few molecular defects in skeletal muscles that are associated with functional limitations in breast cancer. These include circulating cytokines such as TNF-α, IL-1, IL-6, and TGF-β altering the levels or function of myogenic molecules including PAX7, MyoD, and microRNAs through transcriptional regulators such as NF-κB, STAT3, and SMADs. Molecular defects in breast cancer may also include reduced muscle mitochondrial content and increased extracellular matrix deposition leading to energy imbalance and skeletal muscle fibrosis. This review highlights recent evidence that breast cancer-associated molecular defects mechanistically contribute to functional limitations and further provides insights into therapeutic interventions in managing functional limitations, which in turn may help to improve quality of life in breast cancer patients.

Keywords: breast cancer; functional limitations; cachexia; skeletal muscle; microRNA

1. Prevalence of Functional Limitations in Breast Cancer

Breast cancer is one of the most common malignancies affecting one in eight women in the United States. With disease progression, breast cancer causes dramatic systemic effects. Myopenia and cachexia under metastatic settings are observed in ~25% of breast cancer patients, particularly in women with triple-negative breast cancer [1,2]. Functional limitations are observed even before cancer diagnosis and are the major reasons for increased no-cancer related deaths in these patients [3,4]. In a recent study, a cohort of 2202 women with breast cancer was examined and approximately 40% breast cancer patients demonstrated at least one of the functional limitations [5]. Patients with functional limitations exhibit decreased volitional activity, whole body weakness, and fatigue [6–10]. The prevalence of functional limitations in breast cancer patients is dependent on disease stage, age, ethnicity, demographics, and physical compositions [5]. Indeed, functional limitations are more common among older breast cancer patients [5,11]. Women with functional limitations are more likely to be overweight or obese with less physically activity [5,12]. More critically, preclinical and clinical data demonstrate that functional limitations result in significantly shorter survival due to non-cancer causes of death [5,13].
2. Functional Limitation is Likely Due to Skeletal Muscle Dysfunction in Breast Cancer

Growing evidence points to skeletal muscle dysfunction as a major cause of cancer-associated functional limitations. Skeletal muscles represent 40%–50% of the total body mass of a healthy human, making them collectively one of the largest organ systems [14,15]. A defining characteristic of skeletal muscles is its remarkable capacity of generating power for motion of an individual to maintain activities and to ensure the quality of life [16,17]. Thus, muscle force production, fatigue, and twitch characteristics are functional properties that define skeletal muscle quality. Life quality change associated with aging, Duchenne muscular dystrophy (DMD), chronic obstructive pulmonary disease (COPD), and cancer is directly related to these muscle parameters [18–22]. Recently, specific decrements to skeletal muscle’s contractile quality have been identified in cachectic patients and tumor-bearing mice. Women with breast cancer are found to have reduced cross-sectional areas of a single muscle fiber compared with cancer-free controls. In addition, women with breast cancer have reduced fractional content of both subsarcolemmal and intermyofibrillar mitochondria [23]. This observation is consistent with a higher risk of dying due to low levels of muscle mass in women with breast cancer compared to women who have adequate muscle mass [24]. Furthermore, women with higher muscle mass demonstrate improved response to cancer treatment and overall survival [25,26]. Preclinical data from animal models of breast cancer demonstrated that mice with primary mammary tumors have reduced grip strength and declined motor activity [13]. In line with functional limitations, reduction of body fat and increased body free water were observed in the transgenic PyMT mouse model, which represents the luminal B subtype of human breast cancer. Tumor progression also caused decrement of grip strength and reduction of specific force generated by muscle contraction [27], which might be related to the decreased size of muscle fibers and muscle mitochondria [23]. Moreover, breast cancer-associated functional limitations, including muscle weakness and reduced muscle force, correlate with dynamic systemic changes in cytokine/chemokine levels and myogenic regulation (Figure 1). This process involves complex gene expression regulatory networks in the skeletal muscle differentiation hierarchy, which is influenced by the chemokines and cytokines (Figure 1). In breast cancer bone metastasis models, body weight loss is associated with skeletal muscle atrophy and specific changes in the activity of skeletal muscle ryanodine receptors and the calcium (Ca^{2+}) release channel [27].

![Figure 1](image-url). Systemic actions of breast cancer on skeletal muscles lead to functional limitations. Tumors in the breast release growth factors and cytokines into the circulating system. In response to tumors, host immune cells in breast tissue and other organs also release growth factors and cytokines into circulation.
These growth factors and cytokines activate NF-κB in tumors, which further enhance the expression and release of growth factors and cytokines into circulation. Circulating growth factors and cytokines such as TGF-β and TNF-α are transported into skeletal muscles where, through their selective receptors, activate signaling molecules such as NF-κB in myogenic cells. Activated NF-κB regulates a series of molecules through its downstream signaling, feedback regulations, and cross-talk interactions. Tumor-induced reduction of Cox-IV, Prka-γ and Atp2a1 in skeletal muscles results in defective energetic regulation leading to fatigue in breast cancer patients. miR-486 and miR-206 are expressed in the mitochondria of myofibers, but their role in regulating energy remains unknown. Reduced expression of Pax7, MyoD, Myf5/6, and MyoG in skeletal muscles impairs proliferation and differentiation of MuSCs, which is exacerbated by downregulation of Bcl-2, miR-486, and miR-206. These actions lead to myogenic defects such as reduced number and size of myofibers, which is associated with myoatrophy. Downregulation of Mmp-9 and lamin A in skeletal muscles could contribute to increased ECM deposition and myofibrosis. Decreased expression of muscle-specific miR-486 and miR-206 may contribute to their lower levels in circulation. Whether the neuromuscular junction is affected by breast cancer is unknown. Furthermore, whether the tumor itself or cancer treatment affects the gut microbiome, which then changes muscle function, is unknown. Overall, breast cancer-induced impairment of myogenesis, energetic inefficiency, and ECM remodeling leads to functional limitations, which may be manifested clinically as fatigue, muscle weakness, fibromyalgia with and without overt cachexia. Pharmacological intervention through inhibitors of NF-κB such as DMAPT is a promising therapeutic strategy.

3. Altered Cytokines Contribute to Functional Limitations in Breast Cancer

Cytokines are a large family of polypeptides and small proteins, including interleukin (e.g., IL-1, IL-2, IL-4), interferon (IFN-α, β, γ), chemokine, and tumor necrosis factor (TNF) families. Cytokines produced by a variety of cell types exert their actions locally (autocrine and paracrine) or systemically by directly interacting with their specific membrane receptors [28,29]. It has been well established that cytokines secreted by host immune cells in response to tumors and/or by the tumor itself are associated with muscle wasting and functional limitations [30,31]. High plasma levels of IL-6, TNF-α, INF-γ, and IL-1β have been observed in both tumor-bearing animals and cachectic cancer patients [32,33]. Fatigued women who survive breast cancer have significantly higher serum levels of IL-1ra, sTNF-RII, and neopterin than non-fatigued women [34]. This cancer-associated increase in pro-inflammatory activity is common across many diseases including autoimmune, inflammatory, and infectious diseases [35–38]. In our preclinical models, we identified several cytokines/chemokines secreted by mammary tumor lines derived from PyMT+ and Neu+ mice. Both cell lines secreted Gm-csf, Tnf-α, Ccl-2, Ifn-γ, and IL-1α while Timp1 was uniquely secreted by the PyMT+ tumor line. Neu+ mammary tumor line secreted G-csf, Ccl-1, Ccl-5, Cxcl-1, Cxcl-2, Cxcl-10, and Il-1ra. Recently, we measured 33 circulating cytokines/chemokines in plasma of PyMT+ mice by using the Milliplex kit and reported that Tnf-α, Tgf-α, β, G-csf, Il-6, and Gm-csf are elevated, whereas Mip-2 Cxcl-2, Il-9, Cxcl-5, and Il-1α are decreased in tumor-bearing mice compared to age and sex-matched control animals [13]. Thus, the cancer genome has an influence on the type of cytokines/chemokines secreted by cancer cells and consequently on the type and severity of functional limitations. In addition, Peake and colleagues [29] reported that skeletal muscle itself expresses a variety of cytokines, including IFN-γ, TNF-α, LIF, TGF-β, and IL-6. Thus, cytokines produced locally and delivered systemically act on muscles through their specific receptors on myogenic cells. Indeed, myogenic cells express receptors that interact with cytokines including TNF-α, IL-1, IL-6, IFN-γ, and G-CSF [28,39,40].

Many cytokines have been well studied for their actions on cancer-associated muscle wasting and functional limitations. TNF-α directly binds to type 1 TNF-α receptor (TNFR1) on muscle cells resulting in increased reactive oxygen species production via mitochondrial electron transport and activation of NF-κB signaling pathways. NF-κB increases the activity of the ubiquitin/proteasome pathway, which accelerates the regulated degradation of muscle proteins and hence causes muscle.
weakness [41]. Indeed, our recent report showed that increased levels of Tnf-α, Tgf-β, and G-csf in plasma of PyMT+ mice were accompanied by lower muscle mitochondrial activity and muscle dysfunction, which were restored upon inhibition of NF-κB signaling pathways [13]. Interestingly, TNF-α and several other cytokines have been shown to modulate peripheral insulin sensitivity with a mechanism that affects the activation of the insulin receptor and downstream signaling molecules in the skeletal muscles. In addition, TNF-α downregulated insulin-like growth factor-1-dependent signaling pathways that reduced muscle anabolic capacity and enhanced pro-catabolic stimuli [32]. In animal models, treatment with Tgf-β results in muscle atrophy and fibrosis, which causes reduced muscle contraction force [40,42]. In breast cancer with bone metastasis, Tgf-β causes muscle weakness and reduces muscle contractibility [27,43]. Similarly, TGF-β and TNF-α enhance the expression of zinc transporter ZIP14, which blocks the differentiation of muscle stem cells, also called satellite cells (MuSCs), and enhances the loss of myosin heavy chain in the skeletal muscles [44]. Taken together, breast cancer-associated alterations in circulating cytokines contribute to tumor-associated muscle dysfunction (Figure 1). Cancer-specific genomic aberrations may determine the type of cytokines/chemokines produced by cancer cells and pathways affected in the skeletal muscles.

4. Impaired Myogenesis Contributes to Functional Limitations in Breast Cancer

Healthy skeletal muscles have self-renewal capacity via MuSCs to replace injured or dead myofibers [45,46]. Generally, MuSCs are located in niche reservoirs between muscle fibers and extracellular matrix (ECM) and maintained in a quiescent state through activities of several factors including MuSC-enriched transcription factor PAX7 [47,48]. When muscles are injured, MuSCs are activated as myoblasts expressing both PAX7 and MyoD. Myoblasts have proliferating ability to generate as many cells as needed to repair injury. While a portion of myoblasts expressing PAX7, but lacking MyoD, return to quiescent state, the other major portion expressing MyoD, but lacking PAX7, will go on to differentiate and form multinucleated myofibers, and finally replace injured muscle fibers physically and functionally by expressing various contractile proteins, such as myosin heavy chain (MyHC) and skeletal muscle alpha actin [47,49]. Tumors have a pronounced impact on the number of regenerating myofibers in tumor-bearing mdx mice, a popular model to study DMD, compared to the number of regenerating myofibers in tumor-free mdx mice [50]. Skeletal muscle in PDX mouse cancer models also shows reduced regenerative capacity due to dysregulation of Pax7. Pax7 is of importance during myogenesis at any age as Pax7 deficiency in mice results in cell cycle arrest and precocious differentiation of MuSCs, which leads to impaired muscle regeneration [51,52]. As reported previously, Pax7 not only contributes to MuSC activation and self-renewal but also regulates MuSC proliferation and differentiation by acting on its target genes such as Myf5 and MyoD [53,54]. Indeed, MyoD and Myf5 along with other myogenic regulatory factors Myf6 and MyoG, determine the specification of myogenesis and influence MyHC levels and metabolic properties of myofibers [55]. In several of these models, through the P38 MAPK signaling pathway, TNF-α negatively regulates Pax7 expression and contributes to impaired muscle regeneration [56]. In the PyMT+ mammary tumor model, tumor-bearing mice contained lower skeletal muscle Pax7 as well as lower levels of MyoD along with the upregulation of circulating Tnf-α [13]. As illustrated schematically in Figure 1, tumor-derived cytokines/chemokines can impair specific steps of the myogenic program and contribute to functional limitations [13].

In animals that lack inducible nitric oxide synthase (Nos2) expression, MuSCs fail to proliferate and differentiate as a muscle damage-induced increase of Pax7+ MyoD+ double-positive cells is significantly delayed in iNOS-deficient mice along with a significant decrease of MyoG compared to wild type mice [57], indicating that Nos2 is required for effective regeneration of muscle. Nos2 is an enzyme that regulates the synthesis of nitric oxide (NO), which is involved in adult skeletal muscle homeostasis, particularly by mediating muscle regeneration after injury [58–61]. NO promotes activation, fusion, and maintenance of the pool of MuSCs in acutely and chronically damaged muscles [62]. Skeletal
muscle Nos2 expression in PyMT+ mammary tumor mice compared to wild type mice was significantly lower [13], which may have an impact on recovery from injury.

Both BCL-2 and caspase-3 are key regulators of cell apoptosis [63,64]. BCL-2 prevents programmed cell death by inhibiting shuttle proteins BAX and BAK, as enhanced activity of BAX and BAK leads to caspase-3 activation that results in cell death [65,66]. In this regard, in human disease of DMD, enhanced expression of caspase-3 is responsible for myofiber cell death and muscle atrophy [67]. However, a complex role of caspase 3 in skeletal muscle homeostasis is emerging [68]. Caspase 3 null mice compared to wild type mice have reduced muscle mass and myoblasts due to defects in differentiation to myofibers with a parallel downregulation of MyoD and MyoG. These findings are further confirmed in the C2C12 cell line by pharmacologically inhibiting caspase-3 activity. A recent in vivo study showed that inhibition of caspase-3 activity results in a profound disruption in skeletal muscle regeneration [69]. Taken together, caspase-3 is required for MuSC differentiation. With respect to the role of Bcl-2 in myogenesis, Bcl-2+ C2C12 cells co-express markers of early stages of myogenesis, including desmin, MyoD, and Myf-5, and expression of Bcl-2 promotes clonal expansion as the muscle colonies produced by cloned Bcl-2–null cells contain only about half as many cells as the colonies produced by cells with Bcl-2 [70]. Since cytokines such as TNF can influence the expression and/or activity of Bcl-2 and caspase 3, circulating chemokine/cytokine-mediated changes in pro-apoptotic and anti-apoptotic proteins in skeletal muscle could have a profound impact on skeletal muscle function in cancer patients.

Skeletal muscle expresses many miRNAs [71–76] that regulate MuSC proliferation, differentiation, and even muscle force production by modulating gene expression via transcriptional, post-transcriptional, epigenetic mechanisms, and nuclear genome organization [71,77–80]. Cancer affecting the expression of muscle-specific miRNAs has been reported recently in breast cancer [38], rhabdomyosarcoma [81], pancreatic and colorectal cancer [82], gastric cancer [83], and lung cancer [84]. We reported that circulating levels of cardiac and skeletal muscle-enriched miR-486 were lower in breast cancer patients with metastasis compared to healthy individuals [38]. In animal models of breast cancer, lower circulating miR-486 levels correlate with reduced miR-486 expression in skeletal muscle. Furthermore, proteins in the myogenesis (Pax7/MyoD/MyoG) and myofiber survival (Dock3/Pten/Akt) networks, which are regulated by and/or regulate miR-486, are deregulated in skeletal muscles of tumor-bearing transgenic mice compared to controls [38]. In mammary tumor-bearing animals, the downregulation of miR-486 was correlated with the upregulation of circulating Tnf-α, a cytokine that suppresses the expression of miR-486 in myoblasts in culture potentially via NF-κB signaling pathways [13,38]. Thus, miR-486 is an integral part of the myogenesis signaling network that involves Pax7, MyoD, myostatin, and NF-κB [15,85–87] and a potential target of cancer-induced chemokines/cytokines. Reduced skeletal muscle miR-486 expression is a major defect in DMD and transgenic expression of miR-486 in muscle could rescue muscular dystrophy phenotype in animal models [88]. In this regard, based on our preclinical studies, we had previously proposed that loss of miR-486 is responsible for functional limitations in breast cancer patients.

miR-206 is another one of the widely studied miRNAs in skeletal muscles [89]. miR-206 promotes myoblast differentiation of C2C12 cells by blocking cell cycle progression and by inducing myofiber formation [90] via its upstream regulator MyoD and downstream targets Pax7, Pax3, and estrogen receptor-alpha [91]. During myoblast differentiation, MyoD activates miR-206 expression that, in turn, downregulates Pax7 and Pax3 [92–94]. TGF-β and myostatin, which are upregulated in cancer patients, downregulate miR-206 and MyoD levels in skeletal muscle. Skeletal muscles of myostatin knockout mice compared to wild type mice have significantly higher levels of miR-206, while Tgf-β treatment reduces the expression of miR-206 in C2C12 myoblasts [95,96]. Local injection of miR-206 into injured skeletal muscles in rats enhanced muscle regeneration both morphologically and physiologically and effectively inhibited muscle fibrosis [97]. These observations indicate the role of miR-206 in muscle regeneration and muscle function. Thus, it is not surprising that elevated circulating Tgf-β in a PyMT+ mammary tumor model correlated with lower miR-206 in muscles and reduced muscle function
(Figure 1) [13]. In addition, decreased circulating miR-206 is observed in breast cancer [98], renal cell carcinoma [99], melanoma [100], and osteosarcoma [101] patients.

5. Energetic Inefficiency in Skeletal Muscle Contributes to Functional Limitations in Breast Cancer

Cachexia, myopenia, and functional limitations in cancer patients are generally associated with a negative energy balance resulting from either reduced energy production or increased energy expenditure during disease progression [102–104]. Advanced cancer patients have enhanced thermogenesis that increases energy expenditure, which is consistent with the observation in cachectic tumor-bearing animals [105]. It is also known that impairment of the mitochondrial compartment results in decreased ATP production, leading to an energy deficit that becomes even worse since it is coupled with steadily increased energy expenditure. Consistent with this possibility, we have shown reduced muscle mitochondrial content in a PyMT+ mammary tumor model [13], and others have shown reduced ATP levels and increased activity of the energy sensor AMPK [106,107], implying that breast cancer decreases energy production in skeletal muscles. Thus, it is not surprising that skeletal muscles of PyMT+ animals contained lower levels of Atp2a1 [13], an energy transfer enzyme that regulates cellular calcium required for muscle contraction and muscle force production [108]. Interestingly, miR-486 and miR-206 are localized in mitochondria [109], and it is known that miR-486 protects the membrane potential of mitochondria to maintain cell integrity [110,111] through anti-apoptotic BCL-2 family proteins [112,113]. Thus, reduced miR-486 in skeletal muscles of tumor-bearing mice may affect mitochondrial activity that regulates energy production. Collectively, current literature suggests impaired energy production in skeletal muscle as a consequence of cancer, which may be responsible for functional limitation (Figure 1).

6. Altered Extracellular Matrix Contributes to Functional Limitations in Breast Cancer

Extracellular matrix (ECM) consists of a variety of collagens, elastins, fibronectins, tenascins, proteoglycans, and glycosaminoglycans [114]. ECM has dynamic influence on myofibers and muscle function through ECM-directed remodeling events [115,116]. Metalloproteinases (MMPs) play an essential role in ECM remodeling. MMP-2 and MMP-9 degrade collagen type IV of the basement membranes, but also activate focal adhesion kinase that may lead to changes in integrin function and modifications of the cytoskeleton [117]. During early disease stage of DMD, MMP-9, which is elevated due to NF-kB activity, enhances myogenesis. However, during the later disease stage of DMD, MMP-9 level is decreased, leading to the accumulation of fibroadipose tissues and reduced muscle strength [118]. These findings indicate the dual actions of MMP-9 in ECM remodeling and muscle regeneration. We reported that skeletal muscle of mammary tumor-bearing mice compared to wild type mice had elevated ECM deposition, which could be due to a reduction of Mmp-9, [13]. The specific role of Mmp-9 in skeletal muscle remodeling is evident from transgenic and knockout mouse models. Overexpression of Mmp-9 results in myofiber hypertrophy with increased fiber size and contractile force [119]. On the other hand, knockout of the Mmp-9 gene causes muscle atrophy by decreasing fiber cross-sectional areas and altering myofiber type distribution in mouse hindlimb skeletal muscles [120]. Thus, enhanced ECM and decreased Mmp-9 in the skeletal muscle may directly or indirectly contribute to muscle-associated functional limitations (Figure 1). Although MMP-9 has pro-tumorigenic and pro-metastatic roles, MMP-9 targeted therapies failed in clinical studies, potentially due to its requirement for proper skeletal muscle function [121]. MMP members other than MMP-9 could also play a role in skeletal muscle remodeling as the expression of laminin A, a key component of basal membrane in muscle and an Mmp-11 target, which is downregulated in muscles [122]. How cancer causes changes in skeletal muscle ECM is unknown but TGF-β is the likely culprit as TGF-β is implicated in multiple fibrotic diseases [123–125]. TGF-β functions to promote ECM preservation by enhancing collagen synthesis, expression of ECM and profibrotic genes, and inhibiting ECM degradation [126,127] through reduced MMP activity [128–130]. Interestingly, MMP-9 is a positive regulator of TGF-β as MMP-9 is required for the release of active TGF-β [131,132].
Therefore, in cancer, it is likely that circulating TGF-β rather than locally produced TGF-β contributes to enhanced ECM deposition in skeletal muscle.

7. STAT3 Signaling Contributes to Muscle Wasting in Cancer Cachexia

The role of STAT3 in muscle function has been reviewed [133,134]. It is reported that STAT3 contributes to muscle wasting in PDX animal models, as constitutively active STAT3 induces muscle fiber atrophy and exacerbates wasting in cancer cachexia [135,136] in an NF-κB dependent manner [137]. Conversely, inhibition of STAT3 reduces muscle atrophy in cancer [135,136]. These observations are consistent with STAT3 signaling negatively regulating MuSC expansion and skeletal muscle regeneration. Pharmacological inhibition of Stat3 activity enhances MuSC proliferation and muscle repair after injury or during diseased conditions [138,139]. Interestingly, a recent study demonstrated that Stat3 promotes the progression of MuSCs to myogenic lineage through mitochondrial respiration [140], indicating the involvement of mitochondria in muscle repair or muscle wasting in disease conditions. Indeed, JAK2/STAT3 signaling improves cardiac dysfunction by normalizing mitochondrial respiratory function in vivo and in vitro [141] through regulating reactive oxygen species (ROS) formation [142]. Mitochondria are one of the most important sources of ROS in skeletal muscles [143]. The role of ROS and redox signaling in muscle function and muscle regeneration has been reviewed [143–145]. Mitochondrial STAT3 has also been implicated in modulating mitochondrial DNA, mitochondrial transcription, and electron transport chain activity [146–150], further influencing cell survival and metabolism [151,152].

8. NF-κB is a Critical Signaling Relay Engaged in Breast Cancer Associated Functional Limitations

NF-κB represses myogenesis [153,154] and enhances muscle atrophy in various skeletal muscle diseases [155–158]. Activation of NF-κB in response to TNF-α blocks muscle differentiation by enhancing the degradation of the skeletal muscle-specific transcription factor MyoD [154,159]. Apart from TNF-α, increased TGF-β levels in circulation of breast cancer patients [160] can activate TAK1 [161,162], which phosphorylates IKK2 as well as NIK [163,164] and inhibits myogenesis by repressing the expression of MyoD [75,165].

It is noted that the exact role of the NF-κB signaling pathway depends on the state of the skeletal muscle disease and the nature of the disease. For instance, normal skeletal muscles have lower NF-κB activity with different transcriptional profiles compared to stressed muscles. During the late-stage of muscle differentiation, NF-κB acts as a negative regulator of differentiation through the transcriptional repressor YinYang1 [166]. During skeletal muscle atrophy, NF-κB induces murine ring finger-1 [155], an E3 ubiquitin ligase known to be involved in multiple models of skeletal muscle atrophy [167]. NF-κB represses MyoD by inducing its negative regulator PAX7 [50]. Recent studies have demonstrated that myostatin, another protein induced by NF-κB, represses miR-486 expression and inhibitors of this molecule can overcome aging-associated sarcopenia [87,168]. By contrast, miR-486 increases MyoD and its own expression by repressing Pax7 [169]. Furthermore, miR-486 itself controls NF-κB [86]. Mmp-9 regulates NF-κB activity, which further modulates Mmp-9 expression in skeletal muscles. NF-κB mediated induction of nitric oxide has been reported recently [170]. Therefore, there is an intricate signaling network with feed-forward and feedback loops comprising of NF-κB, PAX7, MyoD, myostatin, miR-486, and MMP-9 that regulate skeletal muscle homeostasis, which is disrupted in cancer (Figure 1).

In preclinical studies, activation of NF-κB within muscles results in severe muscle atrophy in mice [50,155]. Inhibition of NF-κB activity preserves muscle mass and reduces oxidative stress in transgenic and PDX tumor-bearing mice [171,172]. In response to denervation-associated muscle degeneration, IKK2 depletion prevents muscle atrophy, maintains fiber type, size, and strength, increases protein synthesis, and reduces protein degradation [156]. Treatment of tumor-bearing animals with a non-specific NF-κB inhibitor prevents tumor-associated muscle wasting via increased MyoD expression and inhibition of ubiquitin-conjugating enzyme E214K in skeletal muscles [173]. Thus, NF-κB and its associated signaling pathways are potential therapeutic targets to treat cancer-related muscle...
dysfunction (Figure 1). Indeed, we reported that the NF-κB inhibitor, dimethylaminoparthenolide (DMAPT), restored skeletal muscle functions including grip strength and motion performance in mammary tumor-bearing mice, accompanied by amelioration of few of the tumor-associated skeletal muscle molecular defects [13].

9. Perspective and Conclusions

Although there has been recent progress in understanding functional limitations in breast cancer, many areas may need to be further explored. The limited progress is mainly due to the perception that breast cancer patients, compared to other cancer patients, rarely experience cachexia. However, considering one in eight women in the United States is diagnosed with breast cancer and 25% of breast cancer patients, particularly those with triple-negative breast cancer, experience cachexia [2,174], additional studies are needed. Furthermore, myopenic obesity, which not only provides a misguided outlook but also impacts chemotherapy tolerability [26,175], is common in breast cancer patients. Lean muscle mass instead of BMI may need to be measured in breast cancer patients to ensure that there is no muscle loss. Mechanistic insights into myopenic obesity are needed to develop therapeutic intervention. In certain cases, adipose atrophy is also a concern as chemokines/ cytokines that cause skeletal muscle dysfunction in cancer also mediate adipose atrophy [176]. Healthy interaction between skeletal muscle and adipocytes is essential as adipokines from adipocytes have a direct influence on myocytes, particularly with respect to metabolic pathways. Cancer-associated changes in neuromuscular and bone-skeletal muscle interaction are gaining attention. Recently, Baraldo and her colleagues reported that permanent deletion of the mTORC1 gene results in instability in the neuromuscular junction, which correlates with reduced treadmill performance [177]. Thus, it might be worthwhile to examine neuromuscular junction structure integrity and stability in skeletal muscles of breast cancer patients or animals with mammary tumors, as innervated skeletal muscle by tissue constructs has higher contractile forces compared to non-innervated skeletal muscle [178]. Gut microbiome is another upcoming area of research and it has recently been shown to affect skeletal muscle size, composition, and function via a proposed gut–muscle axis [179,180]. Since cancer-induced cytokines/chemokines as well as cancer treatments can affect the gut microbiome, it will be interesting to determine an association between the gut microbiome and muscle dysfunction in breast cancer patients. Consistent with this possibility, animals that lack a microbiota in gut have reduced muscle weight, reduced transcription of genes in mitochondria, and reduced neurotransmitter for neuromuscular junction [181]. Since breast cancer is not a single disease and broadly classified into five subtypes [182,183], how each subtype affects skeletal muscle function is unknown. Whether molecular defects are different among subtypes and disease stages of breast cancer remains unknown due to scarce clinical information and limited translational knowledge. Therefore, clinical management of cancer-associated functional limitations remains a great challenge for improving the life quality of cancer patients. In this regard, the majority of the anti-cachexia drugs tested in clinical trials so far have proven ineffective in improving muscle functional performance although a few of them had effects in increasing body weight and lean body mass [184,185].

Overall, our review outlines recent advances in breast cancer-induced functional limitations, highlighting the role of circulating cytokines/chemokines, microRNAs, mitochondria, ECM, and impaired myogenesis, as depicted in Figure 1. Molecular defects outlined here, as well as advances being made in the field of skeletal muscle biology, offer an opportunity to develop pharmacological interventions for the treatment of functional limitations in breast cancer in the near future.

Funding: This work is supported by Department of Veterans Affairs grant BX002764 to HN.

Conflicts of Interest: All authors declare no conflict of interest.
Abbreviations

AKT       Thymoma viral proto-oncogene, also as known protein kinase B (PKB)
AMPK      AMP-activated protein kinase
BAK       Bcl-2 homologous antagonist killer
BAX       Bcl-2-associated X protein
BCL-2     B-cell lymphoma 2
CCL1, 2, or 5     C-C motif chemokine ligand 1, 2, or 5
CCR3      C-C chemokine receptor type 3
CM        Conditioned media
COX-IV    Cytochrome c oxidase subunit 4 isoform 1
CXCL1, 2, 5 or 10 C-X-C motif chemokine ligand 1, 2, 5, or 10
DMAPT     Dimethylaminoparthenolide
DMD       Duchenne muscular dystrophy
DOCK3     Dedicator of cytokinesis 3
ECM       Extracellular matrix
G-CSF     Granulocyte-colony stimulating factor
GM-CSF    Granulocyte-macrophage colony stimulating factor
GTex      Genotype-tissue expression
HOXA9     Homeobox A9
IFN-α, β or γ     Interferon alpha, beta or gamma
IKK       Inhibitor of kappaB kinase
IL-1, 2, 4, 6 or 9 Interleukin 1, 2, 4, 6 or 9
IL-1RA     Interleukin 1 receptor antagonist
MAPK      Mitogen-activated protein kinase
MMPs      Matrix metalloproteinases
MMTV      Mouse mammary tumor virus
MIP2      Macrophage inflammatory protein 2
mTORC1    Mammalian target of rapamycin complex 1
MuSC      Muscle stem cell
MYF5 or 6 Myogen factor 5 or 6
MyHC      Myosin heavy chain
MyoD      Myoblast determination protein 1
MyoG      Myogenin
NF-κB     Nuclear factor-kappa B
NIK       NF-kappa B-inducing kinase
NO        Nitric oxide
Nos2      Nitric oxide synthase
Pax3      Paired box 3
Pax7      Paired box 7
PDX       Patient-derived xenograft
PGC-1β     Peroxisome proliferator-activated receptor gamma co-activator 1 beta
PTEN      Phosphatase and tensin homolog
PyMT      Polyoma middle tumor antigen
ROS       Reactive oxygen species
STAT3     Signal transducer and activator of transcription 3
sTNFRII   Soluble tumor necrosis factor receptor 2
TAK1      Transforming growth factor beta activated kinase 1
TGFB-β    Transforming growth factor beta
TIMP1     TIMP metallopeptidase inhibitor 1
TNF       Tumor necrosis factor
TNFR1     TNF-α receptor type 1
ZIP14      ZRT/IRT-like protein 14
References

1. Consul, N.; Guo, X.; Coker, C.; Lopez-Pintado, S.; Hibshoosh, H.; Zhao, B.; Kalinsky, K.; Acharyya, S. Monitoring metastasis and cachexia in a patient with breast cancer: A case study. Clin. Med. Insights Oncol. 2016, 10, 83–94. [CrossRef] [PubMed]

2. Tomasin, R.; Martin, A.; Cominetti, M.R. Metastasis and cachexia: Alongside in clinics, but not so in animal models. J. Cancer Res. 2019, 10, 1183–1194. [CrossRef] [PubMed]

3. Hendren, E.; Vinik, O.; Faragalla, H.; Haq, R. Breast cancer and dermatomyositis: A case study and literature review. Curr. Oncol. 2017, 24, e429–e433. [CrossRef] [PubMed]

4. Khoo, H.Y.; Tan, W.J.; Cheong, Y.T. Breast cancer with dermatomyositis as initial presentation. Med. J. Malays. 2018, 73, 44–45.

5. Braithwaite, D.; Satariano, W.A.; Sternfeld, B.; Hiatt, R.A.; Ganz, P.A.; Kerlikowske, K.; Moore, D.H.; Slattery, M.L.; Tammemagi, M.; Castillo, A.; et al. Long-term prognostic role of functional limitations among women with breast cancer. J. Natl. Cancer Inst. 2010, 102, 1468–1477. [CrossRef]

6. Baltgalvis, K.A.; Berger, F.G.; Pena, M.M.; Mark Davis, J.; White, J.P.; Carson, J.A. Activity level, apoptosis, and development of cachexia in apc(min/+ ) mice. J. Appl. Physiol. 2010, 109, 1155–1161. [CrossRef]

7. Murphy, K.T.; Chee, A.; Trieu, J.; Naim, T.; Lynch, G.S. Importance of functional and metabolic impairments in the characterization of the c-26 murine model of cancer cachexia. Dis. Model Mech. 2012, 5, 533–545. [CrossRef]

8. Puppa, M.J.; Gao, S.; Narasale, A.A.; Carson, J.A. Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 2014, 28, 998–1009. [CrossRef]

9. Roberts, B.M.; Frye, G.S.; Ahn, B.; Ferreira, L.F.; Judge, A.R. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle. Biochem. Biophys. Res. Commun. 2013, 435, 488–492. [CrossRef]

10. Toth, M.J.; Callahan, D.M.; Miller, M.S.; Tourville, T.W.; Hackett, S.B.; Couch, M.E.; Dittus, K. Skeletal muscle fiber size and fiber type distribution in human breast cancer: Effects of weight loss and relationship to physical function. Clin. Nutr. 2016, 35, 1359–1365. [CrossRef]

11. Sweeney, C.; Schnitz, K.H.; Lazovich, D.; Virnig, B.A.; Wallace, R.B.; Folsom, A.R. Functional limitations in elderly female cancer survivors. J. Natl. Cancer Inst. 2006, 98, 521–529. [CrossRef] [PubMed]

12. Arnold, M.; Jiang, L.; Stefanick, M.L.; Johnson, K.C.; Lane, D.S.; LeBlanc, E.S.; Prentice, R.; Rohan, T.E.; Snively, B.M.; Vitolins, M.; et al. Duration of adulthood overweight, obesity, and cancer risk in the women’s health initiative: A longitudinal study from the United States. PLoS Med. 2016, 13, e1002081. [CrossRef] [PubMed]

13. Wang, R.; Bhat-Nakshatri, P.; Padua, M.B.; Prasad, M.S.; Anjanappa, M.; Jacobson, M.; Finnearty, C.; Sefcik, V.; McElvea, K.; Redmond, R.; et al. Pharmacological dual inhibition of tumor and tumor-induced functional limitations in transgenic model of breast cancer. Mol. Cancer Ther. 2017, 16, 2747–2758. [CrossRef] [PubMed]

14. Janssen, I.; Heymsfield, S.B.; Wang, Z.M.; Ross, R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J. Appl. Physiol. 2000, 89, 81–88. [CrossRef] [PubMed]

15. Small, E.M.; O’Rourke, J.R.; Moresi, V.; Sutherland, L.B.; McNally, J.; Gerard, R.D.; Richardson, J.A.; Olson, E.N. Regulation of p73-kinase/akt signaling by muscle-enriched microRNA-486. Proc. Natl. Acad. Sci. USA 2010, 107, 4218–4223. [CrossRef] [PubMed]

16. Frontera, W.R.; Ochala, J. Skeletal muscle: A brief review of structure and function. Calcif. Tissue Int. 2015, 96, 183–195. [CrossRef]

17. Rowland, L.A.; Bal, N.C.; Periasamy, M. The role of skeletal-muscle-based thermogenic mechanisms in vertebrate endothermy. Biol. Rev. Camb. Philos. Soc. 2015, 90, 1279–1297. [CrossRef]

18. Al-Majid, S.; McCarthy, D.O. Cancer-induced fatigue and skeletal muscle wasting: The role of exercise. Biol. Res. Nurs. 2001, 2, 186–197. [CrossRef]

19. Barreiro, E.; Gea, J. Respiratory and limb muscle dysfunction in copd. COPD 2015, 12, 413–426. [CrossRef]

20. Siegel, I.M. Update on duchenne muscular dystrophy. Compr. Ther. 1989, 15, 45–52.

21. Winningham, M.L.; Nail, L.M.; Burke, M.B.; Brophy, L.; Cimprich, B.; Jones, L.S.; Pickard-Holley, S.; Rhodes, V.; St Pierre, B.; Beck, S.; et al. Fatigue and the cancer experience: The state of the knowledge. Oncol. Nurs. Forum 1994, 21, 23–36. [PubMed]

22. Wolfe, R.R. The underappreciated role of muscle in health and disease. Am. J. Clin. Nutr. 2006, 84, 475–482. [CrossRef] [PubMed]
23. Guigni, B.A.; Callahan, D.M.; Tourville, T.W.; Miller, M.S.; Fiske, B.; Voigt, T.; Korwin-Mihavics, B.; Anathy, V.; Dittus, K.; Toth, M.J. Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress. *Am. J. Physiol. Cell Physiol.* 2018, 315, C744–C756. [CrossRef] [PubMed]

24. Caan, B.J.; Cespedes Feliciano, E.M.; Prado, C.M.; Alexeef, S.; Kroenke, C.H.; Bradshaw, P.; Quesenberry, C.P.; Weltzien, E.K.; Castillo, A.L.; Olobatuyi, T.A.; et al. Association of adiposity and muscle wasting measured by computed tomography with survival in patients with nonmetastatic breast cancer. *JAMA Oncol.* 2018, 4, 798–804. [CrossRef]

25. Shiroyama, T.; Nagatomo, I.; Koyama, S.; Hirata, H.; Nishida, S.; Miyake, K.; Fukushima, K.; Shirai, Y.; Mitsui, Y.; Takata, S.; et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with pd-1 inhibitors: A preliminary retrospective study. *Sci. Rep.* 2019, 9, 2447. [CrossRef]

26. Cespedes Feliciano, E.; Chen, W.Y. Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer. *Proc. Nutr. Soc.* 2018, 77, 382–387. [CrossRef]

27. Waning, D.L.; Mohammad, K.S.; Reiken, S.; Xie, W.; Andersson, D.C.; John, S.; Chiechi, A.; Wright, L.E.; Umanskaya, A.; Niewolna, M.; et al. Excess tgf-beta mediates muscle weakness associated with bone metastases in mice. *Nat. Med.* 2015, 21, 1262–1271. [CrossRef]

28. Zhang, Y.; Pilon, G.; Marette, A.; Baracos, V.E. Cytokines and endotoxin induce cytokine receptors in skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* 2000, 279, E196–E205. [CrossRef]

29. Peake, J.M.; Della Gatta, P.; Suzuki, K.; Nieman, D.C. Cytokine expression and secretion by skeletal muscle cells: Regulatory mechanisms and exercise effects. *Exerc. Immunol. Rev.* 2015, 21, 8–25.

30. Argiles, J.M.; Busquets, S.; Lopez-Soriano, F.J. Cytokines in the pathogenesis of cancer cachexia. *Curr. Opin. Clin. Nutr. Metab. Care* 2003, 6, 401–406. [CrossRef]

31. Fearon, K.; Arends, J.; Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. *Nat. Rev. Clin. Oncol.* 2013, 10, 90–99. [CrossRef] [PubMed]

32. Tisdale, M.J. Cancer cachexia. *Curr. Opin. Gastroenterol.* 2010, 26, 146–151. [CrossRef] [PubMed]

33. Hogan, K.A.; Cho, D.S.; Arneson, P.C.; Samani, A.; Palines, P.; Palines, Y.; Doles, J.D. Tumor-derived cytokines impair myogenesis and alter the skeletal muscle immune microenvironment. *Cytokine* 2018, 107, 9–17. [CrossRef] [PubMed]

34. Bower, J.E.; Ganz, P.A.; Aziz, N.; Fahey, J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom. Med.* 2002, 64, 604–611. [CrossRef]

35. Arend, W.P.; Malyak, M.; Guthridge, C.J.; Gabay, C. Interleukin-1 receptor antagonist: Role in biology. *Annu. Rev. Immunol.* 1998, 16, 27–55. [CrossRef]

36. Diez-Ruiz, A.; Tilz, G.P.; Zangerle, R.; Baier-Bitterlich, G.; Wachter, H.; Fuchs, D. Soluble receptors for tumour necrosis factor-alpha and muscle wasting: A cellular perspective. *Respir. Res.* 2001, 2, 269–272. [CrossRef] [PubMed]

37. Ismaeel, A.; Kim, J.S.; Kirk, J.S.; Smith, R.S.; Bohannon, W.T.; Koutakis, P. Role of transforming growth factor-beta in skeletal muscle fibrosis: A review. *Int. J. Mol. Sci.* 2019, 20, 2446. [CrossRef]

38. Reid, M.B.; Li, Y.P. Tumor necrosis factor-alpha and muscle wasting: A cellular perspective. *Respir. Res.* 2001, 2, 269–272. [CrossRef] [PubMed]

39. Mendiola, C.I.; Gumucio, J.P.; Davis, M.E.; Bromley, C.W.; Davis, C.S.; Brooks, S.V. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. *Muscle Nerve* 2012, 45, 55–59. [CrossRef] [PubMed]

40. Regan, J.N.; Trivedi, T.; Guise, T.A.; Waning, D.L. The role of tgfbeta in bone-muscle crosstalk. *Curr. Osteoporos Rep.* 2017, 15, 18–23. [CrossRef] [PubMed]
44. Wang, G.; Biswas, A.K.; Ma, W.; Kandpal, M.; Coker, C.; Grandgenett, P.M.; Hollingsworth, M.A.; Jain, R.; Tanji, K.; Lomiriconpe-Pintado, S.; et al. Metastatic cancers promote cachexia through zip14 upregulation in skeletal muscle. *Nat. Med.* 2018, 24, 770–781. [CrossRef] [PubMed]

45. Feige, P.; Brun, C.E.; Ritso, M.; Rudnicki, M.A. Orienting muscle stem cells for regeneration in homeostasis, aging, and disease. *Cell Stem Cell* 2018, 23, 653–664. [CrossRef] [PubMed]

46. Rayagiri, S.S.; Ranaldi, D.; Raven, A.; Mohamad Azhar, N.I.F.; Lefebvre, O.; Zammit, P.S.; Borycki, A.G. Basal lamina remodeling at the skeletal muscle stem cell niche mediates stem cell self-renewal. *Nat. Commun.* 2018, 9, 1075. [CrossRef]

47. Dumont, N.A.; Wang, Y.X.; Rudnicki, M.A. Intrinsic and extrinsic mechanisms regulating satellite cell function. *Development* 2015, 142, 1572–1581. [CrossRef]

48. Dueweke, J.J.; Awan, T.M.; Mendias, C.L. Regeneration of skeletal muscle after eccentric injury. *J. Sport Rehabil.* 2017, 26, 171–179. [CrossRef]

49. Zammit, P.S.; Relaix, F.; Nagata, Y.; Ruiz, A.P.; Collins, C.A.; Partridge, T.A.; Beauchamp, J.R. Pax7 and myogenic progression in skeletal muscle satellite cells. *J. Cell Sci.* 2006, 119, 1824–1832. [CrossRef]

50. He, W.A.; Berardi, E.; Cardillo, VM.; Acharyya, S.; Aulino, P.; Thomas-Ahner, J.; Wang, J.; Bloomston, M.; Muscarella, P.; Nau, P.; et al. Nf-kappab-mediated pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. *Clin. Investig.* 2013, 123, 4821–4835. [CrossRef]

51. Von Maltzahn, J.; Jones, A.E.; Parks, R.J.; Rudnicki, M.A. Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. *Proc. Natl. Acad. Sci. USA* 2013, 110, 16474–16479. [CrossRef] [PubMed]

52. Seale, P.; Sabourin, L.A.; Girgis-Gabardo, A.; Mansouri, A.; Gruss, P.; Rudnicki, M.A. Pax7 is required for the specification of myogenic satellite cells. *Cell* 2000, 102, 777–786. [CrossRef]

53. Bajard, L.; Relaix, F.; Lagha, M.; Rocancourt, D.; Daubas, P.; Buckingham, M.E. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates myf5 in muscle progenitor cells in the limb. *Genes Dev.* 2006, 20, 2450–2464. [CrossRef] [PubMed]

54. McMinnell, I.W.; Ishibashi, J.; Le Grand, F.; Punch, V.G.; Addicks, G.C.; Greenblatt, J.F.; Dilworth, F.J.; Rudnicki, M.A. Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex. *Nat. Cell Biol.* 2008, 10, 77–84. [CrossRef] [PubMed]

55. Zammit, P.S. Function of the myogenic regulatory factors myf5, myod, myogenin and mrf4 in skeletal muscle, satellite cells and regenerative myogenesis. *Semin. Cell Dev. Biol.* 2017, 72, 19–32. [CrossRef] [PubMed]

56. Palacios, D.; Mozetta, C.; Consalvi, S.; Caretti, G.; Saccone, V.; Proserpio, V.; Marquez, V.E.; Valente, S.; Mai, A.; Forcales, S.V.; et al. Tnf/p38alpha/polycomb signaling to pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. *Cell Stem Cell* 2010, 7, 455–469. [CrossRef]

57. Rigamonti, E.; Touvier, T.; Clementi, E.; Manfredi, A.A.; Brunelli, S.; Rovere-Querini, P. Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage. *J. Immunol.* 2013, 190, 1767–1777. [CrossRef]

58. De Palma, C.; Clementi, E. Nitric oxide in myogenesis and therapeutic muscle repair. *Mol. Neurobiol.* 2012, 46, 482–692. [CrossRef]

59. Filippin, L.I.; Moreira, A.J.; Marroni, N.P.; Xavier, R.M. Nitric oxide and repair of skeletal muscle injury. *Nitric Oxide* 2009, 21, 157–163. [CrossRef]

60. Stamler, J.S.; Meissner, G. Physiology of nitric oxide in skeletal muscle. *Physiol. Rev.* 2001, 81, 209–237. [CrossRef]

61. Nisoli, E.; Clementi, E.; Carruba, M.O.; Moncada, S. Defective mitochondrial biogenesis: A hallmark of the high cardiovascular risk in the metabolic syndrome? *Circ. Res.* 2007, 100, 795–806. [CrossRef] [PubMed]

62. Buono, R.; Vantaggiato, C.; Pisa, V.; Azzoni, E.; Bassi, M.T.; Brunelli, S.; Sciorati, C.; Clementi, E. Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring vangl2 and cyclic gmp. *Stem Cells* 2012, 30, 197–209. [CrossRef] [PubMed]

63. Porter, A.G.; Janicke, R.U. Emerging roles of caspase-3 in apoptosis. *Cell Death Differ.* 1999, 6, 99–104. [CrossRef] [PubMed]

64. E1more, S. Apoptosis: A review of programmed cell death. *Toxicol. Pathol.* 2007, 35, 495–516. [CrossRef] [PubMed]

65. Tsujimoto, Y. Role of bel-2 family proteins in apoptosis: Apoptosomes or mitochondria? *Genes Cells* 1998, 3, 697–707. [CrossRef] [PubMed]
66. Edlich, F. Bcl-2 proteins and apoptosis: Recent insights and unknowns. Biochem. Biophys. Res. Commun. 2018, 500, 26–34. [CrossRef] [PubMed]

67. Sandri, M.; El Meslemani, A.H.; Sandri, C.; Schjerling, P.; Vissing, K.; Andersen, J.L.; Rossini, K.; Carraro, U.; Angelini, C. Caspase 3 expression correlates with skeletal muscle apoptosis in duchenne and facioscapulohumeral muscular dystrophy. A potential target for pharmacological treatment? J. Neuropathol. Exp. Neurol. 2001, 60, 302–312. [CrossRef]

68. Fernando, P.; Kelly, J.F.; Balazsi, K.; Slack, R.S.; Megeney, L.A. Caspase 3 activity is required for skeletal muscle differentiation. Proc. Natl. Acad. Sci. USA 2002, 99, 11025–11030. [CrossRef]

69. Arnon-Friedman, R.; Dupuis, F.; Fawzi, O.; Renner, R.; Vidick, T. Practical device-independent quantum cryptography via entropy accumulation. Nat. Commun. 2018, 9, 459. [CrossRef]

70. Dominov, J.A.; Dunn, J.J.; Miller, J.B. Bcl-2 expression identifies an early stage of myogenesis and promotes clonal expansion of muscle cells. J. Cell Biol. 1998, 142, 537–544. [CrossRef]

71. Sohi, G.; Dilworth, F.J. Noncoding rnas as epigenetic mediators of skeletal muscle regeneration. FEBS J. 2015, 282, 1630–1646. [CrossRef] [PubMed]

72. Ahmad, A.; Negri, I.; Oliveira, W.; Brown, C.; Asimwe, P.; Sammons, B.; Horak, M.; Jiang, C.; Carson, D. Transportable data from non-target arthropod field studies for the environmental risk assessment of genetically modified maize expressing an insecticidal double-stranded rna. Transgenic Res. 2016, 25, 1–17. [CrossRef] [PubMed]

73. Simionescu-Bankston, A.; Kumar, A. Noncoding rnas in the regulation of skeletal muscle biology in health and disease. J. Mol. Med. 2016, 94, 853–866. [CrossRef] [PubMed]

74. Kusakabe, R.; Inoue, K. Developmental regulation and evolution of muscle-specific micrornas. Semin. Cell Dev. Biol. 2015, 47–48, 9–16. [CrossRef] [PubMed]

75. Liu, D.; Black, B.L.; Derynck, R. Tgf-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by smad3. Genes Dev. 2001, 15, 2950–2966. [CrossRef] [PubMed]

76. Ha, M.; Kim, V.N. Regulation of microrna biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [CrossRef] [PubMed]

77. Catalanotto, C.; Cogoni, C.; Zardo, G. Microrna in control of gene expression: An overview of nuclear functions. Int. J. Mol. Sci. 2016, 17, 1712. [CrossRef]

78. Cai, L.; Chang, H.; Fang, Y.; Li, G. A comprehensive characterization of the function of lincrnas in transcriptional regulation through long-range chromatin interactions. Sci. Rep. 2016, 6, 36572. [CrossRef]

79. Goncalves, T.J.M.; Armand, A.S. Non-coding rnas in skeletal muscle regeneration. Noncoding RNA Res. 2017, 2, 56–67. [CrossRef]

80. D’Souza, R.F.; Bjornsen, T.; Zeng, N.; Aasen, K.M.M.; Raastad, T.; Cameron-Smith, D.; Mitchell, C.J. Micrornas in muscle: Characterizing the powerlifter phenotype. Front. Physiol. 2017, 8, 383. [CrossRef]

81. Li, L.; Sarver, A.L.; Alamgir, S.; Subramanian, S. Downregulation of micrornas mir-1, -206 and -29 stabilizes pax3 and cnd2 expression in rhabdomyosarcoma. Lab. Investig. 2012, 92, 571–583. [CrossRef] [PubMed]

82. Narasimhan, A.; Ghosh, S.; Stretch, C.; Greiner, R.; Bathe, O.F.; Baracos, V.; Damaraju, S. Small maome profiling from human skeletal muscle: Novel mirnas and their targets associated with cancer cachexia. J. Cachexia Sarcopenia Muscle 2017, 8, 405–416. [CrossRef] [PubMed]

83. Yang, Q.; Zhang, C.; Huang, B.; Li, H.; Zhang, R.; Huang, Y.; Wang, J. Downregulation of microrna-206 is a potent prognostic marker for patients with gastric cancer. Eur. J. Gastroenterol. Hepatol. 2013, 25, 953–957. [CrossRef] [PubMed]

84. Lee, D.E.; Brown, J.L.; Rosa-Caldwell, M.E.; Blackwell, T.A.; Perry, R.A., Jr.; Brown, L.A.; Khatri, B.; Seo, D.; Böttje, W.G.; Washington, T.A.; et al. Cancer cachexia-induced muscle atrophy: Evidence for alterations in micrornas important for muscle size. Physiol. Genom. 2017, 49, 253–260. [CrossRef]

85. Buckingham, M.; Rigby, P.W. Gene regulatory networks and transcriptional mechanisms that control myogenesis. Dev. Cell 2014, 28, 225–238. [CrossRef]

86. Song, L.; Lin, C.; Gong, H.; Wang, C.; Liu, L.; Wu, J.; Tao, S.; Hu, B.; Cheng, S.Y.; Li, M.; et al. Mir-486 sustains nf-kappab activity by disrupting multiple nf-kappab-negative feedback loops. Cell Res. 2013, 23, 274–289. [CrossRef]

87. Hitachi, K.; Nakatani, M.; Tsuchida, K. Myostatin signaling regulates akt activity via the regulation of mir-486 expression. Int. J. Biochem. Cell Biol. 2014, 47, 93–103. [CrossRef]
88. Alexander, M.S.; Casar, J.C.; Motohashi, N.; Vieira, N.M.; Eisenberg, I.; Marshall, J.L.; Gasperini, M.J.; Lek, A.; Myers, J.A.; Estrella, E.A.; et al. Microrna-486-dependent modulation of dock3/pten/akt signaling pathways improves muscular dystrophy-associated symptoms. *J. Clin. Investig.* 2014, 124, 2651–2667. [CrossRef]
89. Ma, Y.; Ren, Y.; Dai, Z.J.; Wu, C.J.; Ji, Y.H.; Xu, J. Il-6, il-8 and trf-alpha levels correlate with disease stage in breast cancer patients. *Adv. Clin. Exp. Med.* 2017, 26, 421–426. [CrossRef]
90. Kim, H.K.; Lee, Y.S.; Sivaprasad, U.; Malhotra, A.; Dutta, A. Muscle-specific microrna mir-206 promotes muscle differentiation. *J. Cell Biol.* 2006, 174, 677–687. [CrossRef]
91. Adams, B.D.; Cowee, D.M.; White, B.A. The role of mir-206 in the epidermal growth factor (egf) induced expression by inducing transcription of mir-206. *J. Cell Biol.* 2006, 175, 77–85. [CrossRef] [PubMed]
92. Chen, J.F.; Tao, Y.; Li, J.; Deng, Z.; Yan, Z.; Xiao, X.; Wang, D.Z. Microrna-1 and microrna-206 regulate skeletal muscle oxidative metabolism. *Oxid. Med. Cell Longev.* 2018, 2018, 3097–3103. [CrossRef] [PubMed]
93. Hirai, H.; Verma, M.; Watanabe, S.; Tastad, C.; Asakura, Y.; Asakura, A. Myod regulates apoptosis of myoblasts through microrna-mediated down-regulation of pax3. *J. Cell Biol.* 2010, 191, 347–365. [CrossRef] [PubMed]
94. Rosenberg, M.I.; Georges, S.A.; Asawachaicharn, A.; Analau, E.; Tapscott, S.J. Myod inhibits fstl1 and utrn expression by inducing transcription of mir-206. *J. Cell Biol.* 2006, 175, 77–85. [CrossRef] [PubMed]
95. Winbanks, C.E.; Wang, B.; Beyer, C.; Koh, P.; White, L.; Kantharidis, P.; Gregorevic, P. Tgf-beta regulates mir-206 and mir-29 to control myogenic differentiation through regulation of hdac4. *J. Biol. Chem.* 2011, 286, 13805–13814. [CrossRef] [PubMed]
96. Rachagani, S.; Cheng, Y.; Reecy, J.M. Myostatin genotype regulates muscle-specific mirna expression in mouse pectoralis muscle. *BMC Res. Notes* 2010, 3, 297. [CrossRef]
97. Nakasa, T.; Ishikawa, M.; Shi, M.; Shibuya, H.; Adachi, N.; Ochi, M. Acceleration of muscle regeneration by local injection of muscle-specific micrornas in rat skeletal muscle injury model. *J Cell Mol. Med.* 2010, 14, 2495–2505. [CrossRef]
98. Sameackia, R.; Adorno-Cruz, V.; Bockhorn, J.; Chang, Y.F.; Huang, S.; Prat, A.; Ha, N.; Kibriya, G.; Huo, D.; Zheng, H.; et al. Mir-206 inhibits stemness and metastasis of breast cancer by targeting mkl1/il11 pathway. *Clin. Cancer Res.* 2017, 23, 1091–1103. [CrossRef]
99. Heinemann, F.G.; Tolkach, Y.; Deng, M.; Schmidt, D.; Perner, S.; Kristiansen, G.; Ellinger, J. Serum mir-122-5p and mir-206 expression: Non-invasive prognostic biomarkers for renal cell carcinoma. *Int. J. Clin. Exp. Pathol.* 2015, 8, 3097–3103. [CrossRef]
100. Tian, R.; Liu, T.; Qiao, L.; Gao, M.; Li, J. Decreased serum microrna-206 level predicts unfavorable prognosis in patients with melanoma. *Int. J. Clin. Exp. Pathol.* 2015, 8, 3097–3103. [CrossRef]
101. Zhang, C.; Yao, C.; Li, H.; Wang, G.; He, X. Serum levels of microrna-133b and microrna-206 expression predict prognosis in patients with osteosarcoma. *Int. J. Clin. Exp. Pathol.* 2014, 7, 4194–4203. [PubMed]
102. Argiles, J.M.; Fontes-Oliveira, C.C.; Toledo, M.; Lopez-Soriano, F.J.; Busquets, S. Cachexia: A problem of energetic inefficiency. *J. Cachexia Sarcopenia Muscle* 2019, 10, 465–472. [CrossRef] [PubMed]
103. Harfmann, B.D.; Schroder, E.A.; Kachman, M.T.; Hodges, B.A.; Zhang, X.; Esse, K.A. Muscle-specific loss of bmal1 leads to disrupted tissue glucose metabolism and systemic glucose homeostasis. *Adv. Clin. Exp. Med.* 2017, 26, 3097–3103. [CrossRef] [PubMed]
104. Hardee, J.P.; Montalvo, R.N.; Carson, J.A. Linking cancer cachexia-induced anabolic resistance to skeletal muscle oxidative metabolism. *Oxid. Med. Cell Longev.* 2018, 2018, 7153610. [CrossRef] [PubMed]
105. Hardee, J.P.; Montalvo, R.N.; Carson, J.A. Linking cancer cachexia-induced anabolic resistance to skeletal muscle oxidative metabolism. *Oxid. Med. Cell Longev.* 2017, 2017, 8018197. [CrossRef] [PubMed]
106. Hardee, J.P.; Montalvo, R.N.; Carson, J.A. Linking cancer cachexia-induced anabolic resistance to skeletal muscle oxidative metabolism. *Oxid. Med. Cell Longev.* 2017, 2017, 8018197. [CrossRef] [PubMed]
107. Anastasia, L.; Papini, N.; Colazzo, F.; Palazzolo, G.; Tringali, C.; Dileo, L.; Piccoli, M.; Conforti, E.; Sitzenia, C.; Monti, E.; et al. Neu3 sialidase strictly modulates gm3 levels in skeletal myoblasts cc2c12 thus favoring their differentiation and protecting them from apoptosis. *J. Biol. Chem.* 2008, 283, 36265–36271. [CrossRef]
108. Gehlert, S.; Bloch, W.; Sufr, F. Ca2+-dependent regulations and signaling in skeletal muscle: From electro-mechanical coupling to adaptation. *Int. J. Mol. Sci.* 2015, 16, 1066–1095. [CrossRef]
109. Barrey, E.; Saint-Auret, G.; Bonnamy, B.; Damas, D.; Boyer, O.; Gidrol, X. Pre-microrna and mature microrna in human mitochondria. PLoS ONE 2011, 6, e20220. [CrossRef]

110. Zhang, Y.; Lei, W.; Yan, W.; Li, X.; Wang, X.; Zhao, Z.; Hui, J.; Shen, Z.; Yang, J. Microrna-206 is involved in survival of hypoxia preconditioned mesenchymal stem cells through targeting pim-1 kinase. Stem Cell Res. Ther. 2016, 7, 61. [CrossRef]

111. Hao, W.; Luo, W.; Bai, M.; Li, J.; Bai, X.; Guo, J.; Wu, J.; Wang, M. Microrna-206 inhibited the progression of

112. Deng, M.; Qin, Y.; Chen, X.; Wang, Q.; Wang, J. Microrna-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the muc1 gene. Onco Targets Ther. 2019, 12, 849–859. [CrossRef] [PubMed]

113. Ignotz, R.A.; Massague, J. Transforming growth factor-beta stimulates the expression of fibronectin and

114. Rameshwar, P.; Narayanan, R.; Qian, J.; Denny, T.N.; Colon, C.; Gascon, P. Nf-kappa b as a central mediator

115. Shiba, N.; Miyazaki, D.; Yoshizawa, T.; Fukushima, K.; Shiba, Y.; Inaba, Y.; Imamura, M.; Takeda, S.; Koike, K.; Nakamura, A. Divergent roles of mmp-9 in early and late stages of dystrophic muscles in a mouse model of duchenne muscular dystrophy. Biochim. Biophys. Acta 2015, 1852, 2170–2182. [CrossRef]

116. Massague, J. Tgfbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef]

117. Phanish, M.K.; Winn, S.K.; Dockrell, M.E. Connective tissue growth factor-(ctgf, ccn2)—A marker, mediator

118. Mehan, R.S.; Greybeck, B.J.; Emmons, K.; Byrnes, W.C.; Allen, D.L. Matrix metalloproteinase-9 deficiency

119. Dahiya, S.; Bhatnagar, S.; Hindi, S.M.; Jiang, C.; Paul, P.K.; Kuang, S.; Kumar, A. Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum. Mol. Genet. 2011, 20, 4345–4359. [CrossRef]

120. Mehan, R.S.; Greybeck, B.J.; Emmons, K.; Byrnes, W.C.; Allen, D.L. Matrix metalloproteinase-9 deficiency

121. Winer, A.; Adams, S.; Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol. Cancer Ther. 2018, 17, 1147–1155. [CrossRef] [PubMed]

122. Newby, A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 2006, 69, 614–624. [CrossRef] [PubMed]

123. Phanish, M.K.; Winn, S.K.; Dockrell, M.E. Connective tissue growth factor-(ctgf, ccn2)—A marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 2010, 114, e83–e92. [CrossRef] [PubMed]

124. Leask, A.; Paraparam, S.K.; Shi-Wen, X.; Abraham, D.J. Connective tissue growth factor (ctgf, ccn2) gene regulation: A potent clinical bio-marker of fibroproliferative disease? J. Cell Commun. Signal. 2009, 3, 89–94. [CrossRef] [PubMed]

125. Rameshwar, P.; Narayanan, R.; Qian, J.; Denny, T.N.; Colon, C.; Gascon, P. Nf-kappa b as a central mediator in the induction of tgf-beta in monocytes from patients with idiopathic myofibrosis: An inflammatory response beyond the realm of homeostasis. J. Immunol. 2000, 165, 2271–2277. [CrossRef] [PubMed]

126. Grande, J.P.; Melder, D.C.; Zinsmeister, A.R. Modulation of collagen gene expression by cytokines: Stimulatory effect of transforming growth factor-beta1, with divergent effects of epidermal growth factor and tumor necrosis factor-alpha on collagen type i and collagen type iv. J. Lab. Clin. Med. 1997, 130, 476–486. [CrossRef]

127. Micallef, L.; Vedrenne, N.; Billet, F.; Coulomb, B.; Darby, I.A.; Desmouliaire, A. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenes. Tissue Repair. 2012, 5, S5. [CrossRef] [PubMed]

128. Massague, J. Tgfbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef]

129. Massague, J. Tgfbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef] [PubMed]
[References]

1. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates tgf-beta and promotes tumor invasion and angiogenesis. *Genes Dev.* 2000, 14, 163–176. [PubMed]

2. Imai, K.; Hiramatsu, A.; Fukushima, D.; Pierschbacher, M.D.; Okada, Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. *Biochem. J.* 1997, 322, 809–814. [CrossRef] [PubMed]

3. Zimmers, T.A.; Fishel, M.L.; Bonetto, A. Stat3 in the systemic inflammation of cancer cachexia. *Semin. Cell Dev. Biol.* 2016, 54, 28–41. [CrossRef] [PubMed]

4. Guadagnin, E.; Mazala, D.; Chen, Y.W. Stat3 in skeletal muscle function and disorders. *Int. J. Mol. Sci.* 2018, 19. [CrossRef] [PubMed]

5. Bonetto, A.; Aydogdu, T.; Kunzevitzky, N.; Guttridge, D.C.; Khuri, S.; Koniaris, L.G.; Zimmers, T.A. Stat3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. *PLoS ONE* 2011, 6, e22538. [CrossRef] [PubMed]

6. Tierney, M.T.; Aydogdu, T.; Jin, X.; Zhang, Z.; Zhan, R.; Puzis, L.; Koniaris, L.G.; Zimmers, T.A. Jak/stat3 pathway inhibition blocks skeletal muscle wasting downstream of il-6 and in experimental cancer cachexia. *Am. J. Physiol. Endocrinol. Metab.* 2012, 303, E410–E421. [CrossRef]

7. Ma, J.F.; Sanchez, B.J.; Hall, D.T.; Tremblay, A.K.; Di Marco, S.; Gallouzi, I.E. Stat3 promotes ifngamma/tnfalpha-induced muscle wasting in an nf-kappab-dependent and il-6-independent manner. *EMBO Mol. Med.* 2017, 9, 622–637. [CrossRef]

8. Price, F.D.; von Maltzahn, J.; Bentzinger, C.F.; Dumont, N.A.; Yin, H.; Chang, N.C.; Wilson, D.H.; Frenette, J.; Rudnicki, M.A. Inhibition of jak-stat signaling stimulates adult satellite cell function. *Nat. Med.* 2014, 20, 1174–1181. [CrossRef]

9. Tierney, M.T.; Aydogdu, T.; Sala, D.; Malecova, B.; Gatto, S.; Puri, P.L.; Latella, L.; Sacco, A. Stat3 signaling controls satellite cell expansion and skeletal muscle repair. *Nat. Med.* 2014, 20, 1182–1186. [CrossRef]

10. Sala, D.; Cunningham, T.J.; Stec, M.J.; Etxaniz, U.; Nicoletti, C.; Dall’Agnese, A.; Puri, P.L.; Duester, G.; Latella, L.; Sacco, A. The stat3-fam3a axis promotes muscle stem cell myogenic lineage progression by inducing mitochondrial respiration. *Nat. Commun.* 2019, 10, 1796. [CrossRef]

11. Qaed, E.; Wang, J.; Almoiliqy, M.; Song, Y.; Liu, W.; Chu, P.; Alademi, S.; Alademi, M.; Li, H.; Alshwmi, M.; et al. Phosphocreatine improves cardiac dysfunction by normalizing mitochondrial respiratory function through jak2/stat3 signaling pathway in vivo and in vitro. *Oxid. Med. Cell Longevo.* 2019, 2019, 6521218. [CrossRef] [PubMed]

12. Boengler, K.; Ungefeld, E.; Heusch, G.; Schulz, R. The stat3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation. *Curr. Pharm. Des.* 2013, 19, 6890–6895. [CrossRef] [PubMed]

13. Le Moal, E.; Piaioux, V.; Juban, G.; Groussard, C.; Zouhal, H.; Chazaud, B.; Mounier, R. Redox control of skeletal muscle regeneration. *Antioxid. Redox. Signal* 2017, 27, 276–310. [CrossRef] [PubMed]

14. Powers, S.K.; Ji, L.L.; Kavazis, A.N.; Jackson, M.J. Reactive oxygen species: Impact on skeletal muscle. *Compr. Physiol.* 2011, 1, 941–969. [PubMed]

15. Barbieri, E.; Sestili, P. Reactive oxygen species in skeletal muscle signaling. *J. Signal Transduct.* 2012, 2012, 982794. [CrossRef]

16. Gianotti, T.F.; Castano, G.; Gemma, C.; Burgueno, A.L.; Rosselli, M.S.; Pirola, C.J.; Soookian, M. Mitochondrial DNA copy number is modulated by genetic variation in the signal transducer and activator of transcription 3 (stat3). *Metabolism* 2011, 60, 1142–1149. [CrossRef]

17. Vassilev, A.O.; Lorenz, D.R.; Tibbles, H.E.; Uckun, F.M. Role of the leukemia-associated transcription factor stat3 in platelet physiology. *Leuk. Lymphoma* 2002, 43, 1461–1467. [CrossRef]

18. Phillips, D.; Reiley, M.J.; Aponte, A.M.; Wang, G.; Boja, E.; Gucek, M.; Balaban, R.S. Stoichiometry of stat3 and mitochondrial proteins: Implications for the regulation of oxidative phosphorylation by protein-protein interactions. *J. Biol. Chem.* 2010, 285, 23532–23536. [CrossRef]

19. Wegryn, J.; Potla, R.; Chwae, Y.J.; Sepuri, N.B.; Zhang, Q.; Koeck, T.; Derecka, M.; Szczepanek, K.; Szelag, M.; Gornicka, A.; et al. Function of mitochondrial stat3 in cellular respiration. *Science* 2009, 323, 793–797. [CrossRef]

20. Gough, D.J.; Corlett, A.; Schlessinger, K.; Wegryn, J.; Larner, A.C.; Levy, D.E. Mitochondrial stat3 supports ras-dependent oncogenic transformation. *Science* 2009, 324, 1713–1716. [CrossRef]
151. Boengler, K.; Hilfiker-Kleiner, D.; Heusch, G.; Schulz, R. Inhibition of permeability transition pore opening by mitochondrial stat3 and its role in myocardial ischemia/reperfusion. *Basic Res. Cardiol.* 2010, 105, 771–785. [CrossRef] [PubMed]

152. Shaw, P.E. Could stat3 provide a link between respiration and cell cycle progression? *Cell Cycle* 2010, 9, 4294–4296. [CrossRef] [PubMed]

153. Acharyya, S.; Villalta, S.A.; Bakkar, N.; Bupha-Intr, T.; Janssen, P.M.; Carathers, M.; Li, Z.W.; Beg, A.A.; Ghosh, S.; Sahenk, Z.; et al. Interplay of ikk/nf-kappab signaling in macrophages and myofibers promotes muscle degeneration in duchenne muscular dystrophy. *J. Clin. Investig.* 2007, 117, 889–901. [CrossRef] [PubMed]

154. Guttridge, D.C.; Mayo, M.W.; Madrid, L.V.; Wang, C.Y.; Baldwin, A.S., Jr. Nf-kappab-induced loss of myod messenger rna: Possible role in muscle decay and cachexia [see comments]. *Science* 2000, 289, 2363–2366. [CrossRef]

155. Cai, D.; Frantz, J.D.; Tawa, N.E., Jr.; Melendez, P.A.; Oh, B.C.; Lidov, H.G.; Hasselgren, P.O.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al. Ikkbeta/nf-kappab activation causes severe muscle wasting in mice. *Cell* 2004, 119, 285–298. [CrossRef]

156. Mourkioti, F.; Kratsios, P.; Luedde, T.; Song, Y.H.; Delafontaine, P.; Adami, R.; Parente, V.; Bottinelli, R.; Pasparakis, M.; Rosenthal, N. Targeted ablation of ikk2 improves skeletal muscle strength, maintains mass, and promotes regeneration. *J. Clin. Investig.* 2006, 116, 2945–2954. [CrossRef]

157. Mourkioti, F.; Rosenthal, N. Nf-kappab signaling in skeletal muscle: Prospects for intervention in muscle diseases. *J. Mol. Med.* 2008, 86, 747–759. [CrossRef]

158. Li, H.; Malhotra, S.; Kumar, A. Nuclear factor-kappa b signaling in skeletal muscle atrophy. *J. Mol. Med.* 2008, 86, 1113–1126. [CrossRef]

159. Dogra, C.; Changotra, H.; Mohan, S.; Kumar, A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappab and degradation of myod protein. *J. Biol. Chem.* 2006, 281, 10327–10336. [CrossRef]

160. Kong, F.M.; Anscher, M.S.; Murase, T.; Abbott, B.D.; Iglehart, J.D.; Jirtle, R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. *Ann. Surg.* 1995, 222, 155–162. [CrossRef]

161. Nakano, H.; Shindo, M.; Sakon, S.; Nishinaka, S.; Mihara, M.; Yagita, H.; Okumura, K. Differential regulation of ikappab kinase alpha and beta by two upstream kinases, nf-kappab-inducing kinase and mitogen-activated protein kinase/erk kinase kinase-1. *Proc. Natl. Acad. Sci. USA* 1998, 95, 3537–3542. [CrossRef] [PubMed]

162. Zhao, Q.; Lee, F.S. Mitogen-activated protein kinase/erk kinase kinases 2 and 3 activate nuclear factor-kappab through ikappab kinase-alpha and ikappab kinase-beta. *J. Biol. Chem.* 1999, 274, 8355–8358. [CrossRef] [PubMed]

163. Ninomiya-Tsuji, J.; Kishimoto, K.; Hiyama, A.; Inoue, J.; Cao, Z.; Matsumoto, K. The kinase tak1 can activate the nik-i kappab as well as the map kinase cascade in the il-1 signalling pathway. *Nature* 1999, 398, 252–256. [CrossRef] [PubMed]

164. Wang, C.; Deng, L.; Hong, M.; Akkaraju, G.R.; Inoue, J.; Chen, Z.J. Tak1 is a ubiquitin-dependent kinase of mkk and ikk. *Nature* 2001, 412, 346–351. [CrossRef] [PubMed]

165. Furutani, Y.; Umemoto, T.; Murakami, M.; Matsu, T.; Funaba, M. Role of endogenous tgf-beta family in myogenic differentiation of c2c12 cells. *J. Cell Biochem.* 2011, 112, 614–624. [CrossRef]

166. Wang, H.; Hertlein, E.; Bakkar, N.; Sun, H.; Acharyya, S.; Wang, J.; Carathers, M.; Davuluri, R.; Guttridge, D.C. Nf-kappab regulation of yy1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. *Mol. Cell Biol.* 2007, 27, 4374–4387. [CrossRef]

167. Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.; Nunez, L.; Clarek, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan, K.; et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* 2001, 294, 1704–1708. [CrossRef]

168. Siriett, V.; Salerno, M.S.; Berry, C.; Nicholas, G.; Bower, R.; Kambadur, R.; Sharma, M. Antagonism of myostatin enhances muscle regeneration during sarcopenia. *Mol. Ther.* 2007, 15, 1463–1470. [CrossRef]

169. Dey, B.K.; Gagan, J.; Dutta, A. Mir-206 and -486 induce myoblast differentiation by downregulating pax7. *Mol. Cell Biol.* 2011, 31, 203–214. [CrossRef]
170. Rathnasamy, G.; Sivakumar, V.; Rangarajan, P.; Foulds, W.S.; Ling, E.A.; Kaur, C. Nf-kappab-mediated nitric oxide production and activation of caspase-3 cause retinal ganglion cell death in the hypoxic neonatal retina. *Investig. Ophthalmol. Vis. Sci.* 2014, 55, S878–S889. [CrossRef]

171. Gil da Costa, R.M.; Aragao, S.; Moutinho, M.; Alvarado, A.; Carmona, D.; Casaca, F.; Silva, S.; Ribeiro, J.; Sousa, H.; Ferreira, R.; et al. Hpv16 induces a wasting syndrome in transgenic mice: Amelioration by dietary polyphenols via nf-kappab inhibition. *Life Sci.* 2017, 169, 11–19. [CrossRef] [PubMed]

172. Zhang, L.; Tang, H.; Kou, Y.; Li, R.; Zheng, Y.; Wang, Q.; Zhou, X.; Jin, L. Mg132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. *J. Cancer Res. Clin. Oncol.* 2013, 139, 1105–1115. [CrossRef] [PubMed]

173. Moore-Carrasco, R.; Busquets, S.; Almendro, V.; Palanki, M.; Lopez-Soriano, F.J.; Argiles, J.M. The ap-1 /nf-kappab double inhibitor sp100030 can revert muscle wasting during experimental cancer cachexia. *Int. J. Oncol.* 2007, 30, 1239–1245. [PubMed]

174. Prado, C.M.; Baracos, V.E.; McCargar, L.J.; Reiman, T.; Mourtzakis, M.; Tonkin, K.; Mackey, J.R.; Koski, S.; Pituskin, E.; Sawyer, M.B. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin. Cancer Res.* 2009, 15, 2920–2926. [CrossRef]

175. Sheng, J.Y.; Sharma, D.; Jerome, G.; Santa-Maria, C.A. Obese breast cancer patients and survivors: Management considerations. *Oncology* 2018, 32, 410–417.

176. Vegiopoulos, A.; Rohm, M.; Herzig, S. Adipose tissue: Between the extremes. *EMBO J.* 2017, 36, 1999–2017. [CrossRef]

177. Baraldo, M.; Geremia, A.; Pirazzini, M.; Nogara, L.; Solagna, F.; Turk, C.; Nolte, H.; Romanello, V.; Megighian, A.; Boncompagni, S.; et al. Skeletal muscle mtorc1 regulates neuromuscular junction stability. *J. Cachexia Sarcopenia Muscle* 2019. [CrossRef]

178. Arifuzzaman, M.; Ito, A.; Ikeda, K.; Kawabe, Y.; Kamihira, M. Fabricating muscle-neuron constructs with improved contractile force generation. *Tissue Eng. Part A* 2019, 25, 563–574. [CrossRef]

179. Grosicki, G.J.; Fielding, R.A.; Lustgarten, M.S. Gut microbiota contribute to age-related changes in skeletal muscle size, composition, and function: Biological basis for a gut-muscle axis. *Calcif. Tissue Int.* 2018, 102, 433–442. [CrossRef]

180. Ticinesi, A.; Lauretani, F.; Tana, C.; Nouvenne, A.; Ridolo, E.; Meschi, T. Exercise and immune system as modulators of intestinal microbiome: Implications for the gut-muscle axis hypothesis. *Exerc. Immunol. Rev.* 2019, 25, 84–95.

181. Lahiri, S.; Kim, H.; Garcia-Perez, I.; Reza, M.M.; Martin, K.A.; Kundu, P.; Cox, L.M.; Selkrig, J.; Posma, J.M.; Zhang, H.; et al. The gut microbiota influences skeletal muscle mass and function in mice. *Sci. Transl. Med.* 2019, 11, eaan5662. [CrossRef] [PubMed]

182. Sotiriou, C.; Neo, S.Y.; McShane, L.M.; Korn, E.L.; Long, P.M.; Jazaeri, A.; Martiat, P.; Fox, S.B.; Harris, A.L.; Liu, E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc. Natl. Acad. Sci. USA* 2003, 100, 10393–10398. [CrossRef] [PubMed]

183. Sharma, G.N.; Dave, R.; Sanadaya, J.; Sharma, P.; Sharma, K.K. Various types and management of breast cancer: An overview. *J. Adv. Pharm. Technol. Res.* 2010, I, 109–126. [PubMed]

184. Advani, S.M.; Advani, P.G.; VonVille, H.M.; Jafari, S.H. Pharmacological management of cachexia in adult cancer patients: A systematic review of clinical trials. *BMC Cancer* 2018, 18, 1174. [CrossRef]

185. Penna, F.; Ballaro, R.; Beltra, M.; De Lucia, S.; Garcia Castillo, L.; Costelli, P. The skeletal muscle as an active player against cancer cachexia. *Front. Physiol.* 2019, 10, 41. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).